MAP2K1P1: Unlocking The Potential of Cancer Treatments (G29778)

Target Name: MAP2K1P1

NCBI ID: G29778

MAP2K1P1

Other Name(s): mitogen-activated protein kinase kinase 1 pseudogene 1 | Mitogen-activated protein kinase kinase 1 pseudogene 1

MAP2K1P1: Unlocking The Potential of Cancer Treatments

MAP2K1P1, also known as P182, is a protein that is expressed in various tissues and cell types, including the brain, pancreas, and heart. It is a member of the MAP2K1 family of proteins, which are involved in the regulation of cell proliferation and survival.

MAP2K1P1 is a 120-kDa protein that is expressed in the brain, where it is involved in the regulation of neuronal excitability and synaptic plasticity. It is also expressed in other tissues, including the pancreas and heart, where it plays a role in the regulation of insulin secretion and heart function, respectively.

One of the functions of MAP2K1P1 is to regulate the activity of other proteins that are involved in cell proliferation and survival. This protein does this by phosphate orylating the target proteins, which can then affect their activity and contribute to the regulation of cell growth and differentiation.

Another function of MAP2K1P1 is to regulate the distribution of proteins in the cell. This protein does this by interacting with the target proteins and affecting their localization to specific cellular compartments.

MAP2K1P1 is also involved in the regulation of cellular signaling pathways. This protein does this by interacting with various signaling molecules, including tyrosine kinases, which are involved in the regulation of cell proliferation and survival.

Despite its involvement in various cellular processes, MAP2K1P1 is not well understood, and there is limited research on its biology and function. This lack of understanding has made it difficult to develop effective drugs or biomarkers that target this protein.

In recent years, researchers have been interested in developing drugs that target MAP2K1P1 because of its involvement in cellular signaling pathways. This has led to the development of several potential drugs that are currently in clinical trials, including anastrozolimab, an anti-TIM-3 monoclonal antibody, and Uprotectin-伪, a protectin that can inhibit the activity of MAP2K1P1.

Anastrozolimab is an anti-TIM-3 monoclonal antibody that is designed to target TIM-3, a protein that is involved in the regulation of immune responses and cancer growth. By blocking the activity of TIM-3, anastrozolimab is thought to inhibit the growth and survival of cancer cells.

Uprotectin-伪 is another potential drug that is designed to target MAP2K1P1. This protectin is designed to inhibit the activity of MAP2K1P1 and protect cells from the effects of this protein.

While the development of drugs that target MAP2K1P1 is still in its early stages, it holds great promise as a new treatment option for a variety of diseases. As research continues to advance, it is likely that new treatments will be developed that target this protein and its functions.

Protein Name: Mitogen-activated Protein Kinase Kinase 1 Pseudogene 1

The "MAP2K1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP2K1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets